Colorectal follicular lymphoma: A single-center retrospective study

Table 1 Clinical characteristics of 5 patients

No.	Age	Sex	First occurrence/recurrence (initial site)	Primary/systemic	Nodal lesions	Duodenal lesions	Colorectal site/number	Endoscopic morphology
1	62	M	First occurrence	Primary	(-)	(-)	C, A, R/multiple	Polypoid
2	74	M	First occurrence	Primary	(-)	(-)	C, A/multiple	Polypoid
3	70	F	Recurrence (intraperitoneal LN)	Systemic	(+)	(-)	R/single	Polypoid
4	71	M	Recurrence (stomach)	Systemic	(+)	(-)	R/single	Flat elavated
5	65	F	Recurrence (duodenum)	Primary	(-)	(+)1	C, A (continous)/single	Papular

¹Onset 4 years ago.

M: Male; F: Female; LN: Lymph nodes; C: Cecum; A: Ascending colon; R: Rectum.

Table 2 Clinical course from initial treatment to final outcome

No.	Initial treatment	Short-term changes	Subsequent clinical course	Final outcome (years of survival)
1	R-CVP, BR, R-R	CR	5 years later, intra-colorectal recurrence and transformed into DLBCL after watching for 8 years, and CR was achieved with Pola-BR	Death from other diseases (14 years)
2	ESD, watch1	PR	5 years later, intra-colorectal recurrence, and under watchful waiting without treatment	Alive with disease (8 years)
3	Watch	SD	1 year later, nodal lesions were suggested to have transformed into DLBCL, and CR was achieved with Pola-BR etc.	Alive with disease-free (20 years)
4	ESD, watch1	SD	3 years later, the disease recurred throughout the body, and reached CR with BR	Death from other diseases (29 years)
5	Watch	CR	No recurrence for 10 years	Alive with disease-free (15 years)

¹Rituximab was administered twice.

R-CVP: Rituximab, cyclophosphamide, vincristine, and prednisone; BR: Bendamustine plus rituximab; R-R: Revlimid plus rituximab; ESD: Endoscopic submucosal dissection; CR: Complete remission; PR: Partial response; SD: Stable disease; DLBCL: Diffuse large B-cell lymphoma; Pola: Polatuzumab vedotin.